Investors & Media

Webcast ImageWebcast
27th Annual Piper Jaffray Healthcare Conference (Live)
12/01/15 at 12:00 p.m. ET
27th Annual Piper Jaffray Healthcare Conference
Tuesday, December 1, 2015  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Company Profile
We are the leading company in RNA-targeted drug discovery and development, exploiting a proven novel drug discovery platform we created to generate a broad pipeline of first-in-class or best-in-class antisense drugs. The efficiency and broad applicability of our drug discovery platform allows us to discover and develop antisense drugs to treat a wide range of diseases with an emphasis on cardiovascular, metabolic, severe and rare diseases, including neurological disorders, and cancer. The efficiency of our drug discovery technology allows us to employ a unique business strategy designed to maximize the value of our drugs and technology while maintaining an effective cost structure that limits our cash needs. Our business strategy is supported by our platform technology, our robust pipeline of drugs and our multifaceted partnering strategy, which have enabled us to focus on doing what we do best - to discover and develop novel antisense drugs.
Recent Press ReleasesMore >>
11/10/15Isis Pharmaceuticals Earns $2.8M for Advancing ISIS-DMPK-2.5 Rx in Patients with Myotonic Dystrophy Type I
CARLSBAD, Calif., Nov. 10, 2015 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has earned a $2.8 million milestone payment from Biogen related to the advancement of the ongoing Phase 1/2a study of ISIS-DMPK-2.5Rx in patients with myotonic dystrophy type I (DM1).  "Our collaboration with Biogen has been very productive.  ISIS-DMPK-2.5Rx has rapidly advanced into patients with DM1, and we continue to make progress across the board in our drug discovery prog... 
Printer Friendly Version
11/09/15Isis Reports Financial Results and Highlights for Third Quarter 2015
- 2015 Pro Forma Net Income of $25 Million Significantly Increased Over 2014 - Conference Call Webcast Monday, November 9, 11:30 a.m. ET at CARLSBAD, Calif., Nov. 9, 2015 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) today reported consolidated financial results for the third quarter of 2015 and highlighted recent progress in advancing its pipeline. "Our drugs in development have the potential to make fundamental changes in the way diseases are treat... 
Printer Friendly Version
11/08/15Isis Pharmaceuticals Reports Positive Clinical Data From Lp(a) Lowering Drugs
Webcast to review data scheduled for Sunday, November 8 at 1:00 p.m. Eastern Time CARLSBAD, Calif., and CAMBRIDGE, Mass., Nov. 8, 2015 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), and its subsidiary, Akcea Therapeutics, today announced positive results from a Phase 2 study of ISIS-APO(a)Rx in which patients with high lipoprotein(a), or Lp(a), achieved reductions in Lp(a) of up to 94 percent, with a mean reduction of 71 percent.  Lp(a) is a known driver of cardiovascular disease.... 
Printer Friendly Version
11/06/15Isis Pharmaceuticals to Present at Upcoming Investor Conferences
CARLSBAD, Calif., Nov. 6, 2015 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at the following investor conferences: 24th Annual Credit Suisse Healthcare Conference on Wednesday, November 11, 2015 in Scottsdale, AZ; 2015 Stifel Healthcare Conference on Wednesday, November 18, 2015 in New York, NY; and 27th Annual Piper Jaffray Healthcare Conference on Tuesday, December 1, 20... 
Printer Friendly Version
Upcoming EventsMore >>
27th Annual Piper Jaffray Healthcare Conference
LocationNew York, NY

For more information requests, please visit our Information Request page.

If you are interested in Isis Pharmaceuticals’ investment details,
please visit our Investor FAQ page.

Data provided by Nasdaq. Minimum 15 minutes delayed.